ABUS — Arbutus Biopharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapMomentum Trap

Annual cashflow statement for Arbutus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-154	-63.7	-76.2	-69.5	-72.8
Depreciation
Deferred Taxes
Non-Cash Items	95.6	9.89	6.03	3.43	3.74
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2.23	0.432	0.93	29.2	-18.2
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-71	-51.4	-67.5	-35.4	-85.9
Capital Expenditures	-0.589	-0.229	-0.809	-0.512	-1.01
Purchase of Fixed Assets
Other Investing Cash Flow Items	28.9	-14.7	-11.9	-74.4	51.8
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	28.3	-14.9	-12.7	-74.9	50.8
Financing Cash Flow Items	18.5	0	—	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	37.5	86.7	137	31.8	30.6
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-5.14	20.5	57	-78.5	-4.49